Aurobindo Pharma was established in 1986 as a result of a vision shared by Mr. P. V. Ramprasad Reddy, Mr. K. Nityananda Reddy, and a select group of devoted experts. The business started in 1988 &1989 with a single unit in Pondicherry producing semi-synthetic penicillin (SSP). In 1992, Aurobindo Pharma went public, and in 1995, it floated its shares on the Indian stock exchanges. In addition to dominating the semi-synthetic penicillin industry, it also has a presence in important therapeutic areas like gastroenterology, neurosciences, cardiology, anti-retrovirals, anti-diabetics, and antibiotics, among others. By consistently conducting research, developing, and manufacturing a wide range of pharmaceutical products that adhere to the highest regulatory standards, Aurobindo aims to become the most valued Pharma partner to the tin global pharmaceutical community.
Aurobindo Pharma, one of the biggest R&D institutions in India, has five research centers spanning 16,000 square meters. Additionally, it maintains 3 R&D facilities in the United States. The company's in-house product development skills and over 1700 scientists & analysts provide a speedy turnaround.